A biosimilar version of Pfizer (NYSE: PFE) and Amgen’s (Nasdaq: AMGN) arthritis drug Enbrel (etanercept) is ‘highly similar’ to the reference product, according to US Food and Drug Administration (FDA) staff briefing documents.
Sandoz, the generics and biosimilars division of Swiss pharma giant Novartis (NOVN: VX), is seeking US marketing authorization for GP20915 in a number of conditions including rheumatoid arthritis, psoriasis and psoriatic arthritis.
An FDA committee is due to meet on Wednesday to discuss whether to approve the injection.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze